Methods for limiting development of a skin wound

Patent metadata

Field	Value
Publication number	US-9688724-B2
Application number	US-201314401013-A
Country	US
Kind code	B2
Filing date	Mar 14, 2013
Priority date	May 14, 2012
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.

First claim

We claim:

1. A method for limiting development of a skin wound, comprising administering to a subject that has been exposed to an injurious agent and has developed a pre-wound indication selected from the group consisting of erythemas, blisters, rashes, and pruritis prior to treatment as a result of exposure to the injurious agent, but has not yet developed a skin wound, an amount effective of Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO: 14), or a salt thereof, to limit development of a skin wound.

2. The method of claim 1 , wherein the subject is a human subject.

3. The method of claim 1 , wherein the injurious agent is selected from the group consisting of allergens, skin contact with an irritant, psoriasis, eczema, acne, excessive sun exposure, friction due to chafing of skin, exposure to ionizing radiation, friction on the skin, heat exposure, cold exposure, chemical exposure, contact dermatitis, vesicants, crunching, pinching, or squeezing of the skin; scabies, swimmers' itch, athlete's foot, exposure to poison ivy, exposure to poison oak; body, pubic, or head lice; insect hives, abrasion, contusion, dehydration, excoriation, ultrasound, viruses, autoimmune disease, and xerosis.

4. The method of claim 1 , wherein the injurious agent comprises friction on the skin.

5. The method of claim 1 , wherein the treating comprises slowing the time to wound development resulting from exposure to the injurious agent.

6. The method of claim 1 , wherein limiting development of the skin wound comprises decreasing the severity or decreasing the rate of progression of severity of a subsequently developed wound resulting from exposure to the injurious agent.

7. The method of claim 1 , wherein limiting development of the skin wound comprises preventing wound development resulting from exposure to the injurious agent.

8. A method for treating erythemas, blisters, rashes, and/or pruritis, comprising administering to a subject in need thereof an amount effective to treat the erythema, blister, rash, and/or pruritis of Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO: 14), or a salt thereof.

9. The method of claim 8 , wherein the treating comprises limiting the progression in size, area, and/or depth of the erythema, blister, rash, and/or pruritis.

10. The method of claim 8 , wherein the treating comprises reducing size, area, and/or depth of the erythema, blister, rash, and/or pruritis.

11. The method of claim 8 , wherein the treating comprises increasing rate of healing and/or reducing time to healing of the erythema, blister, rash, and/or pruritis.

12. The method of claim 8 , wherein the treating comprises healing of the erythema, blister, rash, and/or pruritis.

13. A method for treating a disorder selected from the group consisting of contact dermatitis, psoriasis, eczema, acne, and athlete's foot, comprising administering to a subject in need thereof an amount effective to treat the disorder of Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO: 14), or a salt thereof.

14. The method of claim 13 , wherein the method is used to treat contact dermatitis.

15. The method of claim 13 , wherein the method is used to treat psoriasis.

16. The method of claim 13 , wherein the method is used to treat eczema.

17. The method of claim 13 , wherein the method is used to treat acne.

18. The method of claim 13 , wherein the method is used to treat athlete's foot.

19. The method of claim 1 , wherein the polypeptide is administered in a pharmaceutical formulation at a concentration of about 0.001% to about 3% on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.

20. The method of claim 1 , wherein the polypeptide is administered topically.

21. The method of claim 20 , wherein the topical administration comprises administration in a formulation selected from the group consisting of hydrogels, creams, viscoelastics, ointments, pastes, and lotions.

22. The method of claim 20 , wherein the topical formulation comprises about 0.5% to about 4% hydroxyethyl cellulose (HEC) on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.

Assignees

• Univ Southern California

Inventors

• Rodgers Kathleen E
• Dizerega Gere S

Classifications

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• C07K7/14 Primary

  Angiotensins: Related peptides · CPC title

• A61F2013/0051

  for treating insect bite · CPC title

• A61F2013/00365

  use · CPC title

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title